Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore

Table 6 Factors associated with higher out-of-pocket patient payments in a regression model (n=367) ^a

Variables^b	Unstandardized coefficient (B)	95% CI for B		Standard error	Standardized coefficient (B)	p value^c
Variables^b	Unstandardized coefficient (B)	Lower bound	Upper bound	Standard error	Standardized coefficient (B)	p value^c
Length of stay	0.054	0.049	0.060	0.003	0.614	< 0.001
Time to ANC recovery	0.004	-0.004	0.013	0.004	0.031	0.320
ANC at presentation	-0.003	-0.085	0.080	0.042	-0.002	0.948
MASCC score < 21	0.019	-0.033	0.072	0.027	0.022	0.473
Lymphoma	0.067	0.012	0.121	0.028	0.080	0.017
Male gender	0.017	-0.027	0.060	0.022	0.024	0.452
Severe sepsis	0.081	0.020	0.142	0.031	0.085	0.009
Inpatient referral	0.013	-0.048	0.074	0.031	0.013	0.683
18-40 year age group	0.082	0.019	0.144	0.032	0.078	0.011
Therapeutic GCSF treatment	0.101	0.041	0.161	0.030	0.100	0.001
Private Ward (Class A or B1)	0.408	0.359	0.457	0.025	0.499	< 0.001

a. Adjusted R² = 0.691, p < 0.001; b. Only clinically relevant variables that were statistically significant at p value of 0.05 in the univariate analysis were included in the regression model; c. Bolded p values are statistically significant; ANC = absolute neutrophil count; GCSF = granulocyte colony-stimulating factor; MASCC = Multinational Association of Supportive Care in Cancer.

ISSN: 1472-6963